[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

603.P1.20 Oncogenes and Tumor Suppressors Poster II

Oral and Poster Abstracts
Poster Session
Sunday, December 6, 2009: 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)
“Hierarchical” Induction and “Stochastic” Maintenance of Leukemia in An In Vivo Model of t(6;9) Positive Acute Myeloid Leukemia

Claudia Oancea1*, Brigitte Rüster2*, Jessica Roos1*, Anjali Dubey1*, Hannelore Held1*, Tatjana Micheilis1*, Hubert Serve1*, Reinhard Henschler2 and Martin Ruthardt1*

1Hematology, Goethe University, Frankfurt, Germany
2Institute for Transfusion Medicine and Immunohaematology, Blood Transfusion Centre of the German Red Cross, Frankfurt/Main, Germany

Aberrant DNA Methylation and Transcriptional Silencing of DLC-1 in Waldenstrom’s Macroglobulinemia

Lian Xu1*, Bryan Ciccarelli1*, Evdoxia Hatjiharissi, MD2, Guang Yang, PhD3*, Yangsheng Zhou, MD, PhD4*, Zachary Hunter1*, Jenny Sun, MD4*, Ping Gong5*, Xia Liu4*, Hsiuyi Tseng4*, Thea Ioakimidis, MS5*, Robert Manning4*, Christina Hanzis1*, Yang Cao5*, Megan Lewicki5*, Christopher J Patterson6* and Steven Treon, MD, PhD2

1Hematology-Oncology, Dana Farber Cancer Institute, Boston, MA
2Dana-Farber Cancer Institute, Boston, MA
3Medical Oncology, Dana-Farber Cancer Inst., Boston, MA
4Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
5Dana Farber Cancer Institute, Boston, MA
6Waldenstrom's macroglubulinemia center, Dana-Farber Cancer Institute, Boston, MA

Activation of JAK2-V617F by Heterodimeric Receptor Components

Anuradha R. Pradhan, PhD1, Que T. Lambert2*, Lori N. Griner1* and Gary W. Reuther1

1Molecular Oncology, Moffitt Cancer Center, Tampa, FL
2Molecular Oncology, H. Lee. Moffitt Cancer Center of Research Inst., Tampa, FL

Analysis of BCL11A gene Variants  in Hematological Malignancies

Maria Monne1*, Giovanna Piras1*, Antonella Uras1*, Marco Murineddu1*, Angelo D. Palmas1, Giovanna Pira1*, Maria Antonietta Fancello1*, Gian Carlo Latte1*, Alessandro Murgia1*, Angelo Novelli2*, Salvatore Deledda2* and Attilio Gabbas1*

1Hematology, "San Francesco" Hospital, ASLNuoro, Nuoro, Italy
2Dermatology, "San Francesco" Hospital, ASLNuoro, Nuoro, Italy

BCL2A1 Is a Survival and Immortalization Factor for Primitive Hematopoietic Cells

Jean-Yves Metais, PhD*, Thomas Winkler, MD*, Rodrigo T. Calado, MD-PhD and Cynthia E. Dunbar, MD

Hematology Branch, NIH / NHLBI, Bethesda, MD

Bcr/Abl Increases Bcatenin Protein and Activity in An ICSBP-Dependent Manner in Myeloid Cells

Weiqi Huang, Research, Assistant, Professor1*, Elizabeth Horvath, MS2* and Elizabeth A. Eklund, MD2

1Medicine, Northwestern University, Chicago, IL
2Northwestern University Feinberg School of Medicine and Jesse Brown VA Medical Center, Chicago, IL

Constitutive Activation of Rac GTPases Is Induced by Cooperating Mutations in a Human Model of MLL-AF9 Leukemia

Mark Wunderlich, MS*, Kevin A Link, PhD*, Fu-Sheng Chou, MD* and James C. Mulloy, PhD

Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Differential Expression of Mirna* Species in Cancer and the Contribution of MiR-223* to the Development of Acute Myeloid Leukemia

Florian Kuchenbauer, MD1, Sarah M Mah2*, Andrew McPherson3*, Michael Heuser, MD4, Bob Argiropolous, PhD2*, Ryan Morin, PhD5*, Tobias Berg, MD6, David Lai2*, Andrew L Muranyi, BSc7*, Donna E. Hogge, MD, PhD8, Jens Ruschmann, PhD7*, Daniel T. Starczynowski, PhD9, Aly Karsan, MD10, Michael O'Connor, PhD7*, Connie J. Eaves, PhD11, Akira Watahiki, MD, PhD10*, Yuzhuo Wang, PhD10*, Samuel Aparicio, PhD10*, Arnold Ganser, MD, PhD12, Juergen Krauter, MD12*, Jonathan Johnnidis, PhD13*, Marco Marra, PhD14, Fernando Carmago, PhD13* and R. Keith Humphries, MD, PhD11

1Institut für Experimentelle Tumorforschung, Universität Ulm, Ulm, Germany
2Terry Fox Lab, BCCRC, Vancouver, BC, Canada
3BC Genome Science Centre, Vancouver, BC, Canada
4MH Hannover, Hannover, Germany
5Genome Sciences Centre, BC Cancer Research Centre, Vancouver, BC, Canada
6Terry Fox Laboratories, Vancouver, BC, Canada
7Terry Fox Laboratory, B.C. Cancer Agency, Vancouver, BC, Canada
8Division of Hematology and Leukemia/BMT, University of British Columbia, Vancouver, BC, Canada
9Dept. of Medical Biophysics, BC Cancer Research Ctr., Vancouver, BC, Canada
10British Columbia Cancer Rsch. Ctr., Vancouver, BC, Canada
11Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
12Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
13Whitehead Institute for Biomedical Research, Cambridge, MA
14Genome Sciences Center, British Columbia Cancer Agency, Vancouver, BC, Canada

Knock-in of a FLT3 Internal Tandem Duplication Mutation Cooperates with a NUP98-HOXD13 Fusion to Generate Acute Leukemia in a Mouse Model

Sarah M Greenblatt, BS, Biology1*, Li Li, MD, PhD2, Christopher Slape, PhD3*, David Huso4*, Peter D. Aplan, MD5 and Donald Small, MD, PhD1

1Oncology and Pediatrics, Johns Hopkins University, Baltimore, MD
2Johns Hopkins Univ. School of Med., Baltimore, MD
3Bone Marrow Research Laboratory, Royal Melbourne Hospital, Parkville, MD, Australia
4Comparative Medicine, Johns Hopkins School of Medicine, Baltimore, MD
5Genetics Branch, NIH, NCI, CCR, Bethesda, MD

Leukemogenic Transformation by Anterior HOXA-Cluster Genes

Sebastian Buhl1*, Emanuel Maethner2* and Robert K. Slany, PhD1

1Dept. of Genetics, University Erlangen, Erlangen, Bavaria, Germany
2Department of Genetics, University Erlangen, Erlangen, Germany

Loss of Titan (Samd9L), a Candidate -7/7q- Responsible Gene Encoding An Actin Remodeling Regulator, Develops MDS/AML in Cooperation with Evi1 or Fbxl10

Hirotaka Matsui, MD1*, Akiko Nagamachi1*, Yuko Ozaki1*, Daisuke Aki1*, Hiroya Asou, MD1*, Hiroaki Honda, MD2* and Toshiya Inaba, MD1

1Department of Molecular Oncology, Research Institute for Radiation Biology & Medicine, Hiroshima University, Hiroshima, Japan
2Department of Developmental Biology, Research Institute for Radiation Biology & Medicine, Hiroshima University, Hiroshima, Japan

Oligomerization Inhibition Combined with Allosteric Inhibition Abrogates the Transformation Potential of T315I-Positive BCR/ABL

Afsar Ali Mian*, Claudia Oancea*, Zihan Zhao*, Hubert Serve, MD, PhD*, Ottmann Oliver* and Martin Ruthardt, MD*

Hematology, Goethe University, Frankfurt, Germany

Peptides Compete in Human Herpesvirus 8  K1-Fas Complexes Associated with Hyperplasia and Restore Apoptosis

Jillian F Wise, BS1*, Zuzana Berkova, Ph.D.2*, Urszula Daniluk1*, Ronghua Tao, M.D., Ph.D.2*, Steven Ovu3*, Om Prakash4* and Felipe Samaniego, MD5

1Lymphoma/Myeloma, M.D. Anderson Cancer Center, Houston, TX
2Lymphoma/Myeloma, M. D. Anderson Cancer Center, Houston, TX
3Lymphoma, MD Anderson Cancer Center, Houston, TX
4Ochsner Clinic Foundation, New Orleans, LA
5Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX

Role of a Conserved Helicase Motif in the Transformation of Primary Human CD34+ Cells by the NUP98-DDX10 Oncogene

Enas R Yassin, MD1*, Anmaar M Abdul-Nabi, MD2*, Akiko Takeda, PhD3 and Nabeel R. Yaseen, MD, PhD4

1Pathology and Immunology, Washington University in St. Louis, St. Louis, MO
2Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO
3Washington University Sch of Medicine, Saint Louis, MO
4Washington University in St Louis, Saint Louis, MO

The Nuclear Orphan Receptors NR4A1 and NR4A3 as Putative Tumour Suppressor Genes in Aggressive Non-Hodgkin’s Lymphomas

Alexander JA Deutsch1*, Christine Beham-Schmid2*, Werner Linkesch, MD3 and Peter Neumeister, MD1*

1Clinical Hematology, Internal Medicine, Graz, Austria
2Institute of Pathology, Graz, Austria
3Department of Hematology, Med. Univ. Graz, Graz, Austria

The PIM1 Oncogene Accelerates TCL1 Driven Lymphomagenesis in a Double-Transgenic Murine Model

Evelena Ontiveros1, David Dae-Young Kim1, Jeffrey M Calimlim1*, Matthew I. Schrage2*, Quang T Luong1*, Debra Tosity2*, Bao Ngan Doan2*, Brandon Castor2*, Michael A. Teitell2*, Jonathan W Said2* and Sven De Vos1

1Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA
2Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA

The Roles of MLL Holocomplex in Embryogenesis, Hematopoiesis and Tumor Suppression

Akihiko Yokoyama, PhD1*, Francesca Ficara, PhD2, Issay Kitabayashi, PhD1 and Michael L. Cleary, MD2

1Molecular Oncology Division, National Cancer Center Research Institute, Tokyo, Japan
2Pathology, Stanford University School of Medicine, Stanford, CA

Unique Gain-of-Function of Mutated c-CBL Tumor Suppresor in Myeloid Neoplasms

Masashi Sanada1*, Takahiro Suzuki2*, Lee-Yung Shih3, Makoto Otsu4*, Motohiro Kato1*, Satoshi Yamazaki5*, Hiroaki Honda6*, Mamiko Yanagimoto Sakata7*, Keiki Kumano8*, Hideaki Oda9*, Junko Takita10*, Norihiko Kawamata11*, Masafumi Onodera12*, Yasuhide Hayashi13, Mineo Kurokawa8, Shigeru Chiba7, Hiraku Mori14*, Keiya Ozawa15, Mitsuhiro Omine14*, Hiromitsu Nakauchi4, Phillip H Koeffler11* and Seishi Ogawa1

1Cancer Genomics Project, University of Tokyo, Tokyo, Japan
2Division of Hematology, Departiment of Medicine, Jichi Medical University, Shimotsukeshi, Japan
3Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan
4Division of Stem Cell Therapy, Center for Stem Cell and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo, Japan
5ERATO, Japan Science and Technology Agency, Saitama, Japan
6Department of Developmental Biology, Research Institute for Radiation Biology & Medicine, Hiroshima University, Hiroshima, Japan
7University of Tsukuba, Tsukuba, Japan
8Department of Hematology and Oncology, University of Tokyo, Tokyo, Japan
9Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan
10Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
11Division of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA
12National Research Institute for Child Health and Development, Tokyo, Japan
13Hematology/Oncology, Gunma Children's Medical Center, Shibukawa, Japan
14Showa University Fujigaoka Hospital, Yokohama, Japan
15Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan

*signifies non-member of ASH